{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-031589","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.042325+00:00","generated_at":"2026-06-04T01:12:50.773542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY","bullets":["Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.","Trailing twelve-month sales ended Mar 31, 2024: $21.3M, up 33% from $16.0M.","Backlog of orders $9.1M at Mar 31, 2024, down from $9.4M Dec 2023 but up from $2.5M Dec 2022.","Company expects FDA response on Re-Tain CMC Technical Section by May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-031589","json":"https://secwatch.observer/filing/0001213900-24-031589.json","markdown":"https://secwatch.observer/filing/0001213900-24-031589.md","text":"https://secwatch.observer/filing/0001213900-24-031589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/0001213900-24-031589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/ea0203580-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:12:50.773542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97739f75aee747b46c1aa1cc1b045d0f4789d9b5","claim":"IMMUCELL CORP /DE/ reported Q1 2024 results: revenue $ 7.3 million.","evidence_excerpt":"first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended March 31, $ 7.3 million $ 3.4 million $ 3.8 million 111 % During the Twelve-Month Periods Ended March 31, $ 21.3 million $ 16.0 million $ 5.3 million 33 % Total sales during the three-month period ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024031589/0001213900-24-031589-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2024"},{"label":"Revenue","value":"$ 7.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}